{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:10:57Z","timestamp":1788379857289,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T00:00:00Z","timestamp":1353110400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s40261-012-0026-0","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T18:07:07Z","timestamp":1355940427000},"page":"783-790","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetic and Pharmacodynamic Profiles of a Fixed-Dose Combination of Olmesartan Medoxomil and Amlodipine in Healthy Chinese Males and Females"],"prefix":"10.1007","volume":"32","author":[{"given":"Xia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,17]]},"reference":[{"issue":"3 pt 2","key":"26_CR1","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0002-8703(99)70312-1","volume":"138","author":"J He","year":"1999","unstructured":"He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138(3 pt 2):S211\u20139.","journal-title":"Am Heart J"},{"key":"26_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199601043340103","volume":"334","author":"MJ Klag","year":"1996","unstructured":"Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13\u20138.","journal-title":"N Engl J Med"},{"key":"26_CR3","first-page":"341","volume-title":"Clinical trials in cardiovascular disease","author":"PK Whelton","year":"1999","unstructured":"Whelton PK, He J. Blood pressure reduction. In: Hennekens CH, Buring JE, Manson JE, Ridker PM, editors. Clinical trials in cardiovascular disease. Philadelphia: WB Saunders; 1999. p. 341\u201359."},{"key":"26_CR4","first-page":"2228","volume":"26","author":"J He","year":"1995","unstructured":"He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People\u2019s Republic of China. II. Meta-analysis of hypertension and risk of stroke. Stroke. 1995;26:2228\u201332.","journal-title":"Stroke"},{"key":"26_CR5","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(98)03454-0","volume":"352","author":"Eastern Stroke and Coronary Heart Disease Collaborative Research Group","year":"1998","unstructured":"Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 1998;352:1801\u20137.","journal-title":"Lancet"},{"key":"26_CR6","doi-asserted-by":"crossref","unstructured":"He J, Whelton PK, Wu X, Burt VL, Tao S, Roccella EJ, Klag MJ. Comparison of secular trends in prevalence of hypertension in the People\u2019s Republic of China and the United States of America. Am J Hypertens. 1996;9:74A. Abstract.","DOI":"10.1016\/0895-7061(96)81696-7"},{"key":"26_CR7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.HYP.0000040263.94619.D5","volume":"40","author":"D Gu","year":"2002","unstructured":"Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, Huang G, Reynolds RF, Su S, Whelton PK, He J. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension. 2002;40:920\u20137.","journal-title":"Hypertension"},{"issue":"8","key":"26_CR8","first-page":"701","volume":"19","author":"Writing Group of 2010 Chinese Guidelines for the Management of Hypertension","year":"2011","unstructured":"Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Chin J Hypertens. 2011;19(8):701\u201341.","journal-title":"Chin J Hypertens"},{"key":"26_CR9","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC7 Report. JAMA. 2003;289:2560\u201372.","journal-title":"JAMA"},{"key":"26_CR10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1751-7176.2010.00422.x","volume":"13","author":"H Punzi","year":"2011","unstructured":"Punzi H, Shojaee A, Waverczak WF, Maa JF. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. J Clin Hypertens (Greenwich). 2011;13:422\u201330.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"26_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/VHRM.S16852","volume":"7","author":"R Kreutz","year":"2011","unstructured":"Kreutz R. Olmesartan\/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag. 2011;7:183\u201392.","journal-title":"Vasc Health Risk Manag"},{"key":"26_CR12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0091270008322176","volume":"48","author":"S Rohatagi","year":"2008","unstructured":"Rohatagi S, Lee J, Shenouda M, Haworth S, Bathala MS, Allison M, Rubets I, Heyrman R, Noveck R, Salazar DE. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol. 2008;48:1309\u201322.","journal-title":"J Clin Pharmacol"},{"key":"26_CR13","first-page":"323","volume":"64","author":"J Jiang","year":"2009","unstructured":"Jiang J, Liu D, Hu P. Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. Pharmazie. 2009;64:323\u20136.","journal-title":"Pharmazie"},{"issue":"12","key":"26_CR14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5414\/CPP44641","volume":"44","author":"JY Park","year":"2006","unstructured":"Park JY, Kim KA, Park PW, Lee OJ, Kim JS, Lee GH, Ha MC, Park JH, O MJ, Ryu JH. Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Int J Clin Pharmacol Ther. 2006;44(12):641\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"26_CR15","unstructured":"Therapeutic Goods Administration, Department of Health and Ageing, Australian Government. Australian Public Assessment Report for Amlodipine\/Valsartan. Page 11, Table\u00a01. Unknown investigators. Study 2311, investigated the pharmacokinetic bioavailability of valsartan and amlodipine followingfixed 5\/320 mg combination tablet prototypes (test) and free combination (reference) amlodipine 5\u00a0mg and valsartan 320\u00a0mg. Novartis Pharmaceuticals Australia Pty. October 2012."},{"key":"26_CR16","unstructured":"Data on file: Investigator\u2019s Brochure CS-8663. CS8663-A-U112 study. Daiichi Sankyo Co. Ltd; 2008."},{"issue":"19","key":"26_CR17","first-page":"1672","volume":"28","author":"Y Chang","year":"2008","unstructured":"Chang Y, Wen A, Li C, Wang Z, Chen S, Zhao P, Wu Y, Jin X, Wang J, Zhu Y, Wang X. Pharmacokinetics of amlodipine besylate\/atorvastatin calcium combination tablet in healthy volunteers. Chin Hosp Pharm J. 2008;28(19):1672\u20136.","journal-title":"Chin Hosp Pharm J"},{"key":"26_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","volume":"22","author":"JK Faulkner","year":"1986","unstructured":"Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22:21\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"17","key":"26_CR19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/0002-9149(90)91118-P","volume":"66","author":"LM Lopez","year":"1990","unstructured":"Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. Am J Cardiol. 1990;66(17):1269\u201371.","journal-title":"Am J Cardiol"},{"key":"26_CR20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0002-9149(97)89205-3","volume":"77","author":"RA Kloner","year":"1996","unstructured":"Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77:713\u201322.","journal-title":"Am J Cardiol"},{"key":"26_CR21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/hr.2011.189","volume":"36","author":"K Ueno","year":"2012","unstructured":"Ueno K, Sato H. Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs. Hypertens Res. 2012;36:245\u201350.","journal-title":"Hypertens Res"},{"key":"26_CR22","unstructured":"Data on file: Liu DY, Jiang J, Hu P. SS-866 CMB\/02 study, investigated the pharmacokinetics of olmesartan medoxomil\/hydrochlorothiazide FDC tablet and compared with the mono-drug formulation of olmesartan medoxomil and hydrochlorothiazide, respectively. Daiichi Sankyo Co. Ltd; 2008."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0026-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0026-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:49Z","timestamp":1559489329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0026-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,17]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0026-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,17]]}}}